OSE Immunotherapeutics Share Price Deutsche Boerse AG
Stocks
6OP
FR0012127173
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Deutsche Boerse AG
07:02:47 01/09/2026 BST
|
After hours 20:59:58 | |||
| 3.156 EUR | +0.96% |
|
3.184 | +0.89% |
| 08-19 | Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine | RE |
| 06-11 | OSE Immunotherapeutics Recovers Following Oddo BHF Endorsement |  |
| Market Cap | 75.17M 87.14M 70.71M 64.42M 121M 8.27B 122M 836M 325M 4.21B 327M 320M 13.95B | P/E 2026 * |
-2.46x | P/E 2027 * | -2.81x |
|---|---|---|---|---|---|
| Enterprise Value | 116M 134M 109M 99.37M 187M 12.76B 188M 1.29B 502M 6.49B 505M 494M 21.52B | EV / Sales 2026 * |
23.7x | EV / Sales 2027 * | 13.1x |
| Free-Float |
78.15% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : OSE Immunotherapeutics
| 1 day | +1.86% | ||
| 1 week | -3.55% | ||
| Current month | +0.96% | ||
| 1 month | -0.25% | ||
| 3 months | -33.95% | ||
| 6 months | -29.36% | ||
| Current year | -39.77% |
| 1 week | 3.13 |  | 3.17 |
| 1 month | 3.11 | | 3.32 |
| Current year | 2.86 | | 5.57 |
| 1 year | 2.86 | | 7.16 |
| 3 years | 2.86 | | 10.68 |
| 5 years | 2.7 | | 13.5 |
| 10 years | 2.7 | | 15.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Bozec
CEO | Chief Executive Officer | - | 01/10/2025 |
Thomas Gidoin
DFI | Director of Finance/CFO | 43 | 19/08/2025 |
Silvia Comis
CTO | Chief Tech/Sci/R&D Officer | - | 19/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Maryvonne Hiance
BRD | Director/Board Member | 77 | 30/05/2016 |
Brigitte Dreno
BRD | Director/Board Member | 73 | 13/06/2017 |
| Director/Board Member | - | 21/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.96% | -3.55% | - | - | 87.85M | |
| +0.21% | -1.70% | +1.90% | +18.18% | 49.81B | |
| +2.09% | -0.81% | +452.73% | +517.81% | 44.06B | |
| -1.09% | -0.73% | +35.40% | +16.04% | 42.99B | |
| -0.26% | -3.58% | +17.19% | +72.80% | 40.88B | |
| -0.48% | -3.09% | +17.78% | +49.80% | 33.11B | |
| -1.81% | -5.94% | +22.65% | +115.79% | 16.58B | |
| -1.06% | +3.29% | - | - | 17.27B | |
| -1.35% | -2.32% | +10.40% | +25.90% | 14.63B | |
| -2.05% | -5.44% | +72.89% | +36.51% | 13.76B | |
| Average | -0.36% | -1.64% | +78.87% | +106.61% | 30.34B | |
| Weighted average by Cap. | -0.19% | -1.79% | +95.32% | +124.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.9M 5.68M 4.61M 4.2M 7.9M 539M 7.94M 54.49M 21.21M 274M 21.33M 20.87M 909M | 10.53M 12.21M 9.91M 9.02M 16.97M 1.16B 17.06M 117M 45.58M 589M 45.83M 44.84M 1.95B |
| Net income | -30.59M -35.46M -28.77M -26.21M -49.29M -3.37B -49.56M -340M -132M -1.71B -133M -130M -5.68B | -21.47M -24.89M -20.19M -18.4M -34.59M -2.36B -34.78M -239M -92.92M -1.2B -93.44M -91.41M -3.98B |
| Net Debt | 40.79M 47.29M 38.37M 34.96M 65.73M 4.49B 66.09M 454M 177M 2.28B 178M 174M 7.57B | 63.08M 73.13M 59.34M 54.06M 102M 6.94B 102M 702M 273M 3.53B 275M 269M 11.71B |
| Date | Price | Change |
|---|---|---|
| 01/09/26 | €3.156 | +0.96% |
| 31/08/26 | €3.126 | -1.45% |
| 28/08/26 | €3.172 | +0.25% |
| 27/08/26 | €3.164 | +0.25% |
| 26/08/26 | €3.156 | +0.57% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- OSE Stock
- 6OP Stock
Select your edition
All financial news and data tailored to specific country editions
